Rituximab Plus Bendamustine as Front Line Treatment in Frail Elderly (>70 Years) Patients With DLBCL: a Phase II Multicenter Study of the FIL

Exclusion Criteria

• •History of other malignancies within 5 years prior to study entry except for adequately treated carcinoma in situ of the cervix or basal or squamous cell skin cancer
• •Previous exposure to cytotoxic agents
• •Suspect or clinical evidence of CNS involvement by lymphoma
• •HBsAg, HCV or HIV positivity; HBcAb positivity is accepted only with concomitant treatment with Lamivudine
• •AST /ALT \> twice upper the normal range; bilirubin \> twice upper the normal range; serum creatinine \> 2.5 mg /dl
• •Evidence of any severe active acute or chronic infection
• •Concurrent co-morbid medical condition which might exclude administration of full dose chemotherapy
• •Senile dementia
• •Any other co-existing medical or psychological condition that would preclude participation in the study or compromise ability to give informed consent